Slide 1: Phase I/II Trial in Pancreatic Adenocarcinoma (TACTOPS)
PHASE I/II TRIAL IN PANCREATIC ADENOCARCINOMA (TACTOPS) July 22°¢2019 > MARKER
Slide 2: Forward Looking Statement
——————_—— FORWARD LOOKING STATEMENT Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements
Slide 3: Peter Hoang, President & Chief Executive Officer
Peter Hoang President & Chief Executive Officer
Slide 4: Survival Rates Have Not Been Meaningfully Improved in the Last 40 Years
SURVIVAL RATES HAVE NOT BEEN MEANINGFULLY IMPROVED IN THE LAST 40 YEARS Trends in 5-year relative survival rates, US, 1975-2013
Slide 5: Pancreatic Cancer Remains Deadly at Every Stage
———_o PANCREATIC CANCER REMAINS DEADLY AT EVERY STAGE... Five-year relative survival rates by stage at diagnosis, US, 2007-2013 Allstages Local Regional _ Distant Allstages Local Regional Distant. (Gecas Temata 30 3 co B_ Ora cavity & pharynx 6 84 64 39 (oon recur a 30 7 1a) ovary a 3 B 2» Colon 64
Slide 6: While Mortality Rate Remains Stagnant
——————_— «WHILE MORTALITY RATE REMAINS STAGNANT Trends in Age-adjusted Cancer Death Rates, Trends in Age-agjstes Cancer Death Rates, Males, U3, 50'2018 Females! OS 980.2546 109 109 2 g al t Lung & bronchus 2 Eco y & Lung & bronchus 2 stomacn Prostate © | sicmei Colon & rect Z,, ‘Colon & rectum Eales
Slide 7: Brandon G. Smaglo M.D., FACP, Lead Investigator
Brandon G. Smaglo M.D., FACP Lead investigator and Assistant Professor of Oncology at Baylor College of Medicine
Slide 8: Pancreatic Cancer: Therapy Remains Chemotherapy
——————_— PANCREATIC CANCER: THERAPY REMAINS CHEMOTHERAPY « Combination chemotherapy © Adjuvant: FOLFIRINOX or gemcitabine/capecitabine © Palliative: FOLFIRINOX or gemcitabine/nab-paclitaxel ° Side effects ©° Cumulative: fatigue, neuropathy, cytopenias © Repetitive: nausea, vomiting, diarrhea ° Distr
Slide 9: First Line Therapy: ACCORD-11 FOLFIRINOX
FIRST LINE THERAPY ACCORD-I!: FOLFIRINOX GENERATES LONGEST OVERALL SURVIVAL BUT IS HIGHLY TOXIC ¢ All patients with metastatic pancreatic cancer @ FOLFIRINOX vs. gemcitabine A. Overall Survival *¢ FOLFIRINOX option for first line we BeO001 by sated logsrank test * Median OS 11.1 months (vs. 6.8m). a
Slide 10: First Line Therapy: MPACT Gem-Abraxane
FIRST LINE THERAPY MPACT: GEM-ABRAXANE GENERATES SHORTER OVERALL SURVIVAL BUT IS BETTER TOLERATED ¢ All patients with metastatic pancreatic cancer * Gemcitabine/nab-paclitaxel vs. gemcitabine * Gemcitabine/nab-paclitaxel option for first line lessees * Median OS 8.5 months . Events/n (95% C1)_Percen
Slide 11: Phase I/II Pancreatic Trial (TACTOPS): Arm Study
——————_—— PHASE I/II PANCREATIC TRIAL (TACTOPS): 3 ARM STUDY ARM CANCER STATUS. Advanced Advanced Borderline Resectable ENROLLMENT CRITERIA Responding (SD or PR) to initial chemotherapy Failure of or intolerance to initial chemotherapy Effective neoadjuvant ‘therapy MULTITAA T CELLS ‘Administered in
Slide 12: Arm A: T Cells as First Line Therapy + SOC Chemotherapy
FIRST LINE THERAPY ARM A: T CELLS AS FIRST LINE THERAPY + SOC CHEMOTHERAPY Continued same 1* line Three months of chemotherapy ae line Observe to chemotherapy 2 progression regimen Monthly T cells up to 6x * This arm was designed to evaluate the safety and potential efficacy of using MultiTAA cells
Slide 13: Pancreatic Phase I Trial (TACTOPS) Arm A Highlights
FIRST LINE THERAPY PANCREATIC PHASE I TRIAL (TACTOPS) ARM A HIGHLIGHTS ° 10 patients: 9 evaluable, 1 too early 3 confirmed objective responses (OR), out of 9 evaluable patients: 1 complete response (CR) and 2 partial responses (PR) after receiving MultiTAA cells 4 stable disease (SD): Notably, 2 pat
Slide 14: Arm A: Summary of Best Overall Response (RECIST)
Se ARM A: SUMMARY OF BEST OVERALL RESPONSE (RECIST) Patient e ‘Chemotherapy Given ‘gemcitabine/nab-paciitaxel FOLFIRINOX FOLFIRINOX FOLFIRINOX ‘gemcitabine/nab-paciitaxel gemeitabine/nab-pacitaxel FOLFIRINOX ‘gemeitabine/nab-paciitaxel FOLFIRINOX Best RECIST response on T cell Therapy Partial respon
Slide 15: Clinical Response: Patient #1 - Partial Response
CLINICAL RESPONSE: PATIENT #1* - PARTIAL RESPONSE Pre-Treatment After T Cell Treatment (2m) >50% reduction of index lesion Targeted antigens 150 3 100 Shvesot é sracesas § so mss Sorane ° Baseline Cotter chemo sone) Peak post Non-targeted antigens B 180 awn 2 100 Marr a MAGE! S50 MMAGE-AS § MAGE26 M
Slide 16: Clinical Response: Patient #3 - Partial Response
CLINICAL RESPONSE: PATIENT #3 - PARTIAL RESPONSE Pre-Treatment After T Cell Treatment (6m) >40% reduction of index lesion Targeted antigens 4 0 @ Patient had a significant population % 90, survivin, of PRAME-specific cells at baseline, & 60 sNx&01 which may reflect tumor volume g athe decrease prior
Slide 17: Clinical Response: Patient #7 - Complete Response
CLINICAL RESPONSE: PATIENT #7 - COMPLETE RESPONSE Pre-Treatment Targeted antigens Peak post survivin enveson MMAGE-Ad S82 Baseline Cotter eneme alone) Non-targeted antigens sMAgE-CL THage-as MAGE-28 IMAGEA il Baseline (otter creme atone) Peak post Prior to infusion, patient had virtually no detectab
Slide 18: Summary of Aggregate Measurable Tumor: Arm A Patients
SUMMARY OF AGGREGATE MEASURABLE TUMOR ARM A PATIENTS Cchemo-onty ‘chemo + MultiTAA cols leasurement represents sum of all lesions Prior patient experience Unusual findings eh 7
Slide 19: Pancreatic Clinical Trial Outcomes: Arm A
SS PANCREATIC CLINICAL TRIAL OUTCOMES Arm A: T cells + effective chemotherapy 1D Chemotherapy Given Median PES Median O8 me >>> >>> >> >> >>> >>> >t) i nm comes 3 FOLFIRINOX 2)22>22)2)2)222223229222222222292222222 m0) 4 FoLrinNox PPDDDDDPDIDPDIIPPIIIDPIIIPDIIPPDIID 50.03m0) 7 FOLFIRINOX —-PIDPDDDDDD
Slide 20: Arm B: T Cells as Second Line Therapy
SECOND LINE THERAPY ARM B: T CELLS AS SECOND LINE THERAPY Three months of 1 line Monthly T cells up to Observe to chemotherapy 6x progression regimen e Arm B explores the use of MultiTAA cells as a second line therapy for patients who fail first line chemotherapy: ° Patients progressing after chemot
Slide 21: Pancreatic Phase I/II Trial (TACTOPS) Arm B Highlights
PANCREATIC PHASE I/II TRIAL (TACTOPS) ARM B HIGHLIGHTS e 6 patients treated and evaluable * 3 out of 6 patients achieved clinical disease stabilization, which can be considered medically significant in this setting © Results in this setting generally have a median overall survival of approximately 3
Slide 22: Arm B: Summary of Best Overall Response (RECIST)
— Se ARM B: SUMMARY OF BEST OVERALL RESPONSE (RECIST) Patient Best RECIST response on T coll therapy Progression of disease Stable disease (Not assessed) (Not assessed) Progression of disease Progression of disease Best clinical assessment Clinically stable Clinically well; off of any therapy Clinic
Slide 23: TACTOPS Tumor Measurement: Arm B Patients
TACTOPS TUMORI MEASUREMENT: ARM B PATIENTS MultTAA cals ony : al “tumor Sige Cem) 3 ree Asean Tatil Co agmniaton Tes Resssent ‘Secon Roemer ‘netemotheney Goran “Measurement represents sum of al lesions . + Patient 3 progressed before tumor measurements could be taken
Slide 24: Clinical Response: Patient #2 - Stable Disease
CLINICAL RESPONSE: PATIENT #2 - STABLE DISEASE Pre-Treatment = = After T Cell Treatment (6m) sFc/2xi08 Targeted antigens sURVIVIN, aNv-EsO-1 AMAGEAS mssx2 = PRAME Baseline Peak post Non-targeted antigens Baseline Peak post BMAGe26 SMAGEA Patient had a significant expansion of T cells specific to tar
Slide 25: Pancreatic Clinical Trial Outcomes: Arm B
So PANCREATIC CLINICAL TRIAL OUTCOMES Arm B: T cells as second line therapy 10 Reason for Enrolment Gf of oe Ao ec ae >>> >> >>> 9 70 came) 2 Progression on chemo) PPPPPVDPPPDPDDPPDWD som 3 rosresion on chomone GAY IDL os 4. chemotherapy ntterance BPD es g 5 chemotherapy intolerance GA) PPP haar ae
Slide 26: Arm C: Surgical Adjuvant Therapy
ARM C: SURGICAL ADJUVANT THERAPY Neoadjuvant Adjuvant Therapy Therapy ‘ + E> ae > E Up to give five One preoperative additional T cell T cell infusion infusions e Patients with surgically resectable disease are eligible for Arm C © One dose of MultiTAA cells prior to surgery o Resected tumor is anal
Slide 27: Clinical Response: T Cell Infiltration, Expansion and Epitope Spreading
CLINICAL RESPONSE: T CELL INFILTRATION, EXPANSION AND EPITOPE SPREADING Targeted antigens 600. 4, 500: suRviIN 400: =NY-ESO- § 300. RMAGE-AG § 200. msse2 100: sm PRAME of Baseline Peak post Non-targeted antigens Baseline Peak post © Low baseline T cell count prior to infusion © Post infusion, MultiT
Slide 28: Pancreatic Clinical Trial Outcomes: Arm C
C—O PANCREATIC CLINICAL TRIAL OUTCOMES Arm C: Surgical adjuvant therapy i >>> >>> >> >> >>> >>> > J 50 comoy >>> >>> >> >> > > 9 0 camo 3 DPDDIDIIIIIII>> 80 csmoy S =
Slide 29: Question and Answer Session
Slide 30: Appendix
Slide 31: Profile of MultiTAA-T Cells
LL PROFILE OF MULTITAA-T CELLS 120 100 50% § 80 40% Do 8 2 8 60 3 x 2 g ; 24 © 0% 3 10% 5 om i cos om” coe SS Gos” tan tn ie, Be. as porters era Phenotype Safety
Slide 32: MultiTAA T Cell Specificity
MULTITAA T CELL SPECIFICITY sFc/2n108 160 140 120 100 Specificity Targeted antigens onto! 1m No pepmix im SURVIVIN mNY-Esoa mi MAGE-Aa mi ssxz i PRAME